Could a phosphate drug also stop kidney stones?
NCT ID NCT06481150
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether Tenapanor, a drug approved for kidney disease, can reduce oxalate absorption from food and lower the risk of kidney stones. Eighteen healthy adults without a history of stones took the drug or a placebo, and their urine oxalate levels were compared. The goal was to see if blocking the same gut pathway used for phosphate also blocks oxalate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPEROXALURIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UT Southwestern Medical Center
Dallas, Texas, 75390, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.